Managing diabetes often means following a strict routine of medications, healthy eating, regular exercise, and in many cases, daily insulin injections. For many patients, taking insulin every day can become a challenge, affecting treatment adherence and overall blood sugar control.
The introduction of AWIQLI® (Insulin Icodec) 700 U/mL, the world's first once-weekly basal insulin, represents an important advancement in diabetes care. With just one injection every week, AWIQLI offers a more convenient option for eligible patients who require long-acting insulin therapy.
AWIQLI contains Insulin Icodec, an ultra-long-acting basal insulin designed to provide stable blood glucose control for an entire week with a single injection.
Unlike conventional basal insulins that require daily administration, AWIQLI maintains its glucose-lowering effect over seven days, reducing the number of injections from approximately 365 injections per year to just 52.
Insulin Icodec is engineered to remain active in the body for an entire week. After injection, it is slowly released into the bloodstream, providing continuous background insulin support.
This helps:
The biggest advantage is convenience. Patients need only one scheduled injection every week instead of daily insulin injections.
Clinical studies have demonstrated that once-weekly insulin can provide glycemic control comparable to daily basal insulin when used appropriately.
Missing daily insulin doses is common among many patients. A weekly dosing schedule may help improve adherence and reduce missed doses.
Fewer injections can reduce treatment fatigue, making diabetes management less stressful for many people.
AWIQLI is supplied in a prefilled injection pen designed for convenient self-administration after appropriate training by a healthcare professional.
Your healthcare provider may consider AWIQLI if you:
The suitability of AWIQLI depends on your medical history, current medications, blood glucose control, and other individual factors. It should only be started under medical supervision.
Although AWIQLI offers significant convenience, patients should remember:
Not necessarily. The decision to start once-weekly insulin depends on:
A diabetes specialist or physician will determine whether AWIQLI is appropriate for your treatment plan.
No. AWIQLI is a basal (long-acting) insulin. Some patients may still require mealtime (rapid-acting) insulin depending on their diabetes management plan.
Yes. Your doctor will recommend choosing one fixed day every week and maintaining that schedule.
Follow your healthcare provider's instructions. Do not take extra doses without medical advice.
The arrival of once-weekly basal insulin marks an exciting milestone in diabetes treatment. By reducing injection frequency while maintaining effective blood glucose control, AWIQLI has the potential to improve convenience and support better adherence for appropriate patients.
While no insulin therapy replaces the importance of a healthy lifestyle, regular monitoring, and medical follow-up, innovations like AWIQLI can make living with diabetes simpler and more manageable.
AWIQLI represents an innovative step forward in insulin therapy, offering eligible patients the convenience of one injection per week while aiming to provide effective basal glucose control. If you or a family member is managing diabetes with daily insulin, speak with your healthcare provider to find out whether once-weekly insulin therapy may be an appropriate option.
Disclaimer: This article is intended for educational purposes only and should not be considered medical advice. AWIQLI is a prescription medicine. Always consult a qualified healthcare professional before starting, stopping, or changing any diabetes medication.
